Feature Latest Stories
Findings from the 2015 AACR Annual Meeting, including findings for pembrolizumab in lung cancer, new PARP inhibitor data, phase III data on pembrolizumab versus ipilimumab, and promising findings for the combination of nivolumab and ipilimumab in melanoma, with insight from Eric Whitman, MD.
In this segment, Roy S. Herbst, MD, PhD, and Anne S. Tsao, MD, explore the use of targeted therapy in non-small cell lung cancer. View Now >>
Most Popular Right Now